Clinical Trials
21 trialsIMPACT
University of Utah
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
Roswell Park Cancer Institute
High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
University of Washington
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia
The First Hospital of Jilin University
A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China
IASO104
Institute of Hematology & Blood Diseases Hospital, China
CARE-Heme
University of Alabama at Birmingham
UltraFrailMM
University of Utah
Registry for Adults With Plasma Cell Disorders (PCD's)
UNC Lineberger Comprehensive Cancer Center
Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma
Thomas Jefferson University
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
The First Affiliated Hospital of Soochow University
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
Institute of Hematology & Blood Diseases Hospital, China
CAREMM-004
Institute of Hematology & Blood Diseases Hospital, China
CAREMM-002
Institute of Hematology & Blood Diseases Hospital, China
A Study of CT0596 in Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota